Pay in 4 interest-free payments of $7.26 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Stahl quote: "Follow the FDA label and never get anybody better" [22:10] When GLP-1s aren't appropriate [24:01] Case study: patient on paliperidone gaining weight despite tirzepatide [25:52] Discovery of nucleus tractus solitaris [28:26] The "are we allowed to prescribe this?" debate [29:10] Valproic acid, propranolol, and scope of practice [30:01] Bipolar disorder, obesity, and mood episode frequency [30:49] Moving beyond the monoamine hypothesis [31:19] UK paper: no proof depression is serotonin deficiency [33:23] Alternative treatments: TMS, ketamine, GLP-1s [34:03] Dr
Tackling Bioavailability Challenges for the Next Generation of Small Molecules With small molecules continuing to make up the majority share of new drug approvals, the future is promising for oral drug development, and the innovation potential is significant
This is the second receptor engaged by Tirzepatide (the "twincretin" target)
Glucagon-like peptide 1 receptor stimulation as a means of neuroprotection
This process stimulates skin renewal and encourages the growth of new, healthier skin
